NEW YORK (GenomeWeb) – Abbott's $5.8 billion deal to acquire Alere announced earlier this week is a sign of the potential strength of the point-of-care diagnostics market, including the burgeoning molecular portion of the market, and could set off M&A activity in that segment, according to industry analysts.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.